NCT07005180View on ClinicalTrials.gov

Low-dose Carbon Monoxide (HBI-002) Trial to Evaluate Safety, Tolerability, PK, and Biomarkers in Parkinson's Disease

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

August 31, 2025

Primary Completion Date

December 31, 2025

Study Completion Date

March 31, 2026

Conditions
Parkinson Disease
Interventions
DRUG

HBI-002

Oral liquid containing carbon monoxide

DRUG

Vehicle (placebo)

Vehicle control (placebo)

Sponsors
All Listed Sponsors
lead

Hillhurst Biopharmaceuticals, Inc.

INDUSTRY

NCT07005180 - Low-dose Carbon Monoxide (HBI-002) Trial to Evaluate Safety, Tolerability, PK, and Biomarkers in Parkinson's Disease | Biotech Hunter | Biotech Hunter